Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Lind

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1988
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancerH Anderson, J Wagstaff, D Crowther, et al.
British Journal of Cancer|April 1, 1992
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancerM J Lind, B M Cantwell, M J Millward, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
International Journal of Oncology|July 16, 2004
Chromosomal alterations in breast cancer revealed by multicolour fluorescence in situ hybridizationM B Watson, H Bahia, J N E Ashman, et al.
British Journal of Cancer|February 9, 2006
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopyD J Manton, A Chaturvedi, A Hubbard, et al.
British Journal of Cancer|March 1, 1995
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerM J Lind, L Gumbrell, B M Cantwell, et al.
Cancer Treatment Reviews|January 1, 1993
Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic resultsA H Calvert, M J Lind, M M Millward, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)M J Millward, D R Newell, V Mummaneni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancerM J Millward, D R Newell, K Yuen, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1988
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancerH Anderson, J Wagstaff, D Crowther, et al.
British Journal of Cancer|April 1, 1992
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancerM J Lind, B M Cantwell, M J Millward, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
International Journal of Oncology|July 16, 2004
Chromosomal alterations in breast cancer revealed by multicolour fluorescence in situ hybridizationM B Watson, H Bahia, J N E Ashman, et al.
British Journal of Cancer|February 9, 2006
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopyD J Manton, A Chaturvedi, A Hubbard, et al.
British Journal of Cancer|March 1, 1995
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerM J Lind, L Gumbrell, B M Cantwell, et al.
Cancer Treatment Reviews|January 1, 1993
Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic resultsA H Calvert, M J Lind, M M Millward, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)M J Millward, D R Newell, V Mummaneni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancerM J Millward, D R Newell, K Yuen, et al.
Pageof 5